Skip to main content
Clinical Trials/NCT00092612
NCT00092612CompletedPhase 3

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.

Organon and Co0 sites372 target enrollmentStarted: May 1, 2003Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
372
Primary Endpoint
Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment

Study Overview

Brief Summary

The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.

Detailed Description

The duration of treatment is 10 weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with elevated cholesterol and coronary heart disease

Exclusion Criteria

  • Patients who have cholesterol levels within normal ranges as identified by the study

Outcomes

Primary Outcomes

Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment

Secondary Outcomes

  • Safety and tolerability.

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials